News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Relypsa, Inc. (RLYP) Completes Enrollment Of Phase 1 Onset-Of-Action Study For Patiromer


2/5/2014 9:31:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a clinical-stage biopharmaceutical company, today announced that patient enrollment for its Phase 1 onset-of-action trial of patiromer for the treatment of hyperkalemia has been completed. This is the final clinical trial that Relypsa expects to include in its New Drug Application (NDA), planned to be filed with the U.S. Food and Drug Administration (FDA) during the third quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES